Patents by Inventor Kieu Mong LAM
Kieu Mong LAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12673963Abstract: Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.Type: GrantFiled: February 11, 2021Date of Patent: July 7, 2026Assignee: GENEVANT SCIENCES GMBHInventors: James Heyes, Kieu Mong Lam, Richard J. Holland, Wenxuan Zhang
-
Publication number: 20250332112Abstract: Certain embodiments of the invention provide ionizable lipids having optimized clearance properties. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising ionizable lipids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.Type: ApplicationFiled: January 31, 2023Publication date: October 30, 2025Applicant: GENEVANT SCIENCES GMBHInventors: Richard J. Holland, Kieu Mong Lam, Dayna Louie, James Heyes, Alan D. Martin, Mark Wood, Wenxuan Zhang
-
Publication number: 20250281422Abstract: Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.Type: ApplicationFiled: May 27, 2025Publication date: September 11, 2025Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. ABRAMS, James HEYES, Richard J. HOLLAND, Kieu Mong LAM, Mark WOOD
-
Patent number: 12357705Abstract: The invention provides PEG-conjugated lipids of formula (I): A-B-C (I) wherein A, B, and C have any of the values defined in the specification, as well as compositions comprising the PEG-conjugated lipids of formula (I), nucleic acid lipid nanoparticles comprising the PEG-conjugated lipids of formula (I), and methods of using the PEG-conjugated lipids of formula (I), the compositions, and the nucleic acid nanoparticles.Type: GrantFiled: November 8, 2019Date of Patent: July 15, 2025Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Kieu Mong Lam, Mark Wood
-
Patent number: 12350383Abstract: Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.Type: GrantFiled: November 8, 2019Date of Patent: July 8, 2025Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. Abrams, James Heyes, Richard J. Holland, Kieu Mong Lam, Mark Wood
-
Publication number: 20250114476Abstract: The present disclosure provides poly(alkyloxazoline)-lipid conjugates, lipid particles comprising such conjugates, and methods of administering the lipid particles for nucleic acid delivery to cells or subjects.Type: ApplicationFiled: January 30, 2023Publication date: April 10, 2025Applicant: Genevant Sciences GmbHInventors: James HEYES, Kieu Mong LAM, Richard J. HOLLAND
-
Patent number: 12251470Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.Type: GrantFiled: November 8, 2019Date of Patent: March 18, 2025Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Petra Schreiner
-
Publication number: 20240148663Abstract: The invention provides a compound of compound of formula (I): or a salt thereof, wherein R1, n, L, and X have any of the values described herein, as well as compositions and lipid nanoparticles comprising a compound of formula I, and their use for delivering therapeutic agents such as siRNA and mRNA.Type: ApplicationFiled: December 20, 2021Publication date: May 9, 2024Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Richard J. HOLLAND, Kieu Mong LAM, Alan D. MARTIN, Mark WOOD, Wenxuan ZHANG
-
Publication number: 20240065982Abstract: Certain embodiments of the invention provide lipid nanoparticles for delivery nucleic acid therapeutics to the lungs.Type: ApplicationFiled: July 8, 2021Publication date: February 29, 2024Applicant: GENEVANT SCIENCES GMBHInventors: James Heyes, Kieu Mong Lam, Lorne Ralph Palmer
-
Publication number: 20230150926Abstract: Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.Type: ApplicationFiled: March 12, 2021Publication date: May 18, 2023Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Kieu Mong Lam, Richard J. Holland
-
Publication number: 20230139594Abstract: Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.Type: ApplicationFiled: February 11, 2021Publication date: May 4, 2023Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Kieu Mong LAM, Richard J. HOLLAND, Wenxuan ZHANG
-
Publication number: 20220168222Abstract: The invention provides lipid nanoparticles and formulations containing lipid nanoparticles.Type: ApplicationFiled: April 24, 2020Publication date: June 2, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Alan D. MARTIN
-
Publication number: 20220160899Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.Type: ApplicationFiled: November 1, 2021Publication date: May 26, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. ABRAMS, James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Stephen P. REID, Edward D. YAWORSKI
-
Publication number: 20220133636Abstract: Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.Type: ApplicationFiled: November 8, 2019Publication date: May 5, 2022Inventors: Michael J. ABRAMS, James HEYES, Richard J. HOLLAND, Kieu Mong LAM, Mark WOOD
-
Publication number: 20220072154Abstract: The invention provides PEG-conjugated lipids of formula (I): A-B-C (I) wherein A, B, and C have any of the values defined in the specification, as well as compositions comprising the PEG-conjugated lipids of formula (I), nucleic acid lipid nanoparticles comprising the PEG-conjugated lipids of formula (I), and methods of using the PEG-conjugated lipids of formula (I), the compositions, and the nucleic acid nanoparticles.Type: ApplicationFiled: November 8, 2019Publication date: March 10, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Kieu Mong LAM, Mark WOOD
-
Publication number: 20220031847Abstract: The invention provides methods and compositions for delivering a nucleic acid to a cell or the cytosol of the target cell. The method includes contacting the cell with, 1) a membrane-destabilizing polymer; and 2) a nucleic acid conjugate. The nucleic acid conjugate includes a targeting ligand bound to an optional linker and a nucleic acid.Type: ApplicationFiled: November 4, 2019Publication date: February 3, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Kieu Mong LAM
-
Publication number: 20220001029Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (b) a cationic lipid of formula CL1 or CL2, and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid to a patient (e.g. a human) or to a cell.Type: ApplicationFiled: November 8, 2019Publication date: January 6, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Kieu Mong LAM, Alan D. MARTIN, Petra SCHREINER
-
Publication number: 20220000778Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.Type: ApplicationFiled: November 8, 2019Publication date: January 6, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Petra SCHREINER
-
Patent number: 11191849Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.Type: GrantFiled: June 30, 2017Date of Patent: December 7, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. Abrams, James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Stephen P. Reid, Edward D. Yaworski
-
Publication number: 20190240354Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.Type: ApplicationFiled: June 30, 2017Publication date: August 8, 2019Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. ABRAMS, James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Stephen P. REID, Edward D. YAWORSKI
